Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

NCT06499857 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT06499857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06499857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
Lead sponsor
University of Chicago
Phase
Phase 3
Overall status
Recruiting
Start date
April 14, 2025
Completion date
June 30, 2028
Enrollment
200 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, overweight or obesity